As per the agreement, Myriad will adopt RainDance’s ThunderStorm Target Enrichment System for its next-generation sequencing based Hereditary Cancer Panel (HCP) test.
Myriad Genetics president Mark Capone said that the ThunderStorm System offers unparalleled genomic coverage, the ability to detect large gene rearrangements, workflow benefits, and favorable cost profile to sequence gene panels suitable for a high throughput commercial laboratory to the company.
The HCP test is expected to provide the physicians and patients with actionable, life-saving, information on a broad spectrum of cancers and to give complete assessment of inherited cancer risk.
RainDance CEO and president Roopom Banerjee said that Myriad’s ThunderStorm System selection for their HCP test validates the product differentiation and innovative technology.
"With our proprietary platform, Myriad is establishing a new industry standard for next-generation sequencing of cancer and inherited disease," Banerjee added.
RainDance’s ThunderStorm System uses a single-molecule droplet technology for sequence enrichment.
Myriad is working to integrate RainDance’s technology into its next-generation HCP test that will assess numerous high-prevalence genes that play a critical role in inherited cancer risk.